STOCK TITAN

ADARx Reports Third Quarter 2026 Financial Results and Provides Business Updates

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

ADARx Pharmaceuticals (ADRX) reported third-quarter 2026 results and completed financings generating approximately $602.5 million in aggregate gross proceeds. The IPO comprised 30,187,500 shares at $17.00 each; the concurrent AbbVie private placement comprised 5,255,542 shares. Cash, cash equivalents and short-term investments totaled $901.0 million at September 30, excluding approximately $62.3 million in net option-exercise proceeds received October 1. ADARx expects these funds to support operations into 2030.

Quarterly collaboration revenue rose to $2.217 million from $1.555 million a year earlier, while net loss widened to $28.117 million from $17.883 million. Three agazisiran Phase 2 trials advanced, and onvuzosiran received FDA Fast Track designation for hereditary angioedema prevention. ADARx expects agazisiran data during 2027 and onvuzosiran Phase 3 topline data by year-end 2027.

Loading...
Loading translation...
16 points · 1 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 10 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major pointIPO and concurrent AbbVie private placement generated approximately $602.5 million in aggregate gross proceeds. 42% of market cap
  • Moderate pointThird-quarter collaboration revenue increased to $2.217 million from $1.555 million in 2025.
  • Moderate pointAgazisiran advanced three Phase 2 trials covering renal diseases, paroxysmal nocturnal hemoglobinuria and geographic atrophy.
  • Minor pointCash, equivalents and short-term investments totaled $901.0 million at September 30, 2026, excluding October option proceeds.
  • Minor pointUnderwriters’ option exercise added approximately $62.3 million net proceeds on October 1, 2026.
11 minor points
  • Minor point. Forward-looking: it has not happened yet and may not happen.ADARx expects existing funds and October option proceeds to fund operating expenses and capital requirements into 2030.
  • Minor pointNine-month collaboration revenue increased to $5.103 million from $1.763 million in 2025.
  • Minor pointOnvuzosiran received FDA Fast Track designation in August 2026 for prevention of hereditary angioedema attacks.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Agazisiran IgAN data are anticipated mid-2027 for nine-month urine protein reduction and 2H 2027 for one-year kidney-function stabilization.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Agazisiran Phase 2 data in C3G and paroxysmal nocturnal hemoglobinuria are anticipated in 2H 2027.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Onvuzosiran Phase 3 STOP-HAE topline data are anticipated by year-end 2027.
  • Minor point. Forward-looking: it has not happened yet and may not happen.ADX-626 Phase 2a/b initiation for secondary stroke prevention is anticipated in 2027.
  • Minor point. Forward-looking: it has not happened yet and may not happen.ADX-626 planning includes exploratory studies for stroke prevention in patients with atrial fibrillation.
  • Minor point. Forward-looking: it has not happened yet and may not happen.ADX-077 Phase 1 initiation in obesity is anticipated in 2027.
  • Minor point. Forward-looking: it has not happened yet and may not happen.ADX-199 Phase 1 initiation is anticipated by year-end 2027 or early 2028.
  • Minor pointThird-quarter loss per share narrowed to $1.74 from $1.85 in 2025.

Negative

  • Major pointIPO issuance of 30,187,500 shares at $17.00 dilutes existing holders.
  • Moderate pointThird-quarter net loss widened to $28.117 million from $17.883 million in 2025.
  • Moderate pointThird-quarter research and development expenses rose to $26.713 million from $19.416 million in 2025.
  • Minor pointConcurrent AbbVie private placement issued 5,255,542 shares, adding dilution.
  • Minor pointNine-month net loss widened to $76.543 million from $51.527 million in 2025.
5 minor points
  • Minor pointNine-month research and development expenses rose to $75.032 million from $49.381 million in 2025.
  • Minor pointThird-quarter general and administrative expenses rose to $7.681 million from $5.146 million in 2025.
  • Minor pointNine-month general and administrative expenses rose to $19.195 million from $14.399 million in 2025.
  • Minor pointThird-quarter interest income fell to $3.479 million from $4.622 million in 2025.
  • Minor pointNine-month loss per share widened to $6.46 from $5.35 in 2025.

News Explained

ADARx completed its IPO and concurrent AbbVie placement, issuing 30,187,500 and 5,255,542 new shares, respectively; these issuances increase the share count and reduce existing holders’ percentage ownership, absent offsetting changes.

Key Figures

Aggregate gross proceeds: Approximately $602.5 million Cash and short-term investments: $901.0 million Cash runway: Into 2030 +4 more
Aggregate gross proceeds
Approximately $602.5 million
IPO and concurrent private placement
Cash and short-term investments
$901.0 million
As of September 30, 2026
Cash runway
Into 2030
Expected funding for projected operating expenses and capital expenditure requirements
Collaboration revenue
$2.2 million vs. $1.6 million
Third quarter 2026 vs. third quarter 2025
Net loss
$28.1 million vs. $17.9 million
Third quarter 2026 vs. third quarter 2025
Ongoing Phase 2 trials
Three trials
Agazisiran in complement-mediated diseases
Topline data timing
By year-end 2027
Phase 3 STOP-HAE trial of onvuzosiran

Historical Context

1 past event · Latest: Oct 01
1 event
  1. Oct 01

    IPO closing

    24h Move
    -6.6%

    IPO and AbbVie private placement raised approximately $602.5 million gross; IPO shares were priced at $17.00.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

sirna, fast track designation, upcr
3 terms
sirna medical
"next-generation siRNA therapeutics"
Small interfering RNA (siRNA) is a short strand of genetic material that binds to and destroys the messenger RNA that carries instructions for making a specific protein, effectively switching that gene off. Investors care because siRNA is a platform for precise medicines: successful trials or approvals can create high-value drugs, while delivery challenges, manufacturing complexity, patent positions and regulatory risk can sharply affect a biotech company's prospects.
fast track designation regulatory
"Received Fast Track designation for HAE"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.
upcr medical
"mid-2027 (9-month UPCR reduction data)"
UPCR (urine protein-to-creatinine ratio) is a lab measure that compares the amount of protein to creatinine in a single urine sample to estimate how much protein the kidneys are leaking each day. For investors, shifts in UPCR reported in clinical trials or drug safety data act like a dashboard warning for kidney health, and can strongly affect a therapy’s clinical success, regulatory chances, and commercial prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

– Completed initial public offering (IPO) and concurrent private placement generating aggregate gross proceeds of approximately $602.5 million; cash position expected to fund operations into 2030 –

– Advanced three Phase 2 clinical trials for agazisiran for the treatment of complement-mediated diseases –

– Received Fast Track designation for onvuzosiran for HAE –

SAN DIEGO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (“ADARx” or the “Company”) (Nasdaq: ADRX), a late-clinical stage biotechnology company developing next-generation siRNA therapeutics, today reported financial results for the third quarter ended September 30, 2026, and provided a summary of recent business highlights.

“We have made significant progress across our pipeline of next-generation siRNA therapeutics, bolstered by the successful completion of our IPO and concurrent private placement. These financings provide the resources to advance three clinical-stage programs in parallel, bring two advanced preclinical candidates into the clinic, and support additional IND filings as we expand our pipeline,” said Zhen Li, Ph.D., President and Chief Executive Officer of ADARx. “As the siRNA field evolves, we see tremendous opportunity to expand the range of diseases these therapeutics can address. We believe that our progress with differentiated liver-targeted programs and targeted delivery to extrahepatic tissues positions us to advance our mission of delivering life-changing treatments to patients with unmet medical needs.”

Third Quarter 2026 and Recent Business Highlights

  • Agazisiran – Advancing three Phase 2 clinical trials for the treatment of complement-mediated diseases: ADARx continued to advance three Phase 2 clinical trials ongoing in: (1) renal diseases, including IgA nephropathy (IgAN), complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN); (2) paroxysmal nocturnal hemoglobinuria (PNH); and (3) geographic atrophy (GA) secondary to age-related macular degeneration (AMD), to support its potential as a pipeline-in-a-product opportunity. ADARx intends to explore additional dosing regimens in its Phase 2 IgAN and PNH clinical trials.
  • Onvuzosiran – Received Fast Track designation for HAE: In August 2026, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to onvuzosiran for prophylaxis to prevent attacks of hereditary angioedema (HAE). Onvuzosiran is currently being evaluated in the Phase 3 STOP-HAE clinical trial (NCT06960213).
  • ADX-626 – Advanced clinical development and Phase 2 planning in secondary stroke prevention (SSP) and stroke prevention in atrial fibrillation (AFib): Phase 2 planning for ADARx’s Factor XI (FXI) program is underway for development in SSP and for exploratory studies in stroke prevention in patients with AFib. Determination has been made to not evaluate higher doses after the third dose cohort (400 mg) in the ongoing Phase 1 trial, and the Company intends to evaluate higher doses in its planned Phase 2 clinical trial.
  • Closed IPO and concurrent private placement for aggregate gross proceeds of approximately $602.5 million: ADARx closed its IPO of 30,187,500 shares of its common stock, including 3,937,500 shares issued and sold on October 1, 2026 upon the underwriters’ exercise in full of their option to purchase additional shares, at a price of $17.00 per share. All of the shares of common stock were offered by ADARx and gross proceeds from the IPO, before deducting underwriting discounts and commissions and other offering expenses, were $513.2 million. Together with gross proceeds of $89.3 million from the 5,255,542 shares issued and sold in the concurrent private placement with AbbVie, aggregate gross proceeds from the IPO and concurrent private placement totaled approximately $602.5 million. ADARx’s common stock began trading on the Nasdaq Global Select Market under the ticker symbol “ADRX” on September 25, 2026.
  • Expanded leadership team with board and executive appointments: Executive leader and current K2 Therapeutics CEO, Ying Huang, Ph.D., was appointed to the Board of Directors and veteran human resources leader Robert Ackles was appointed as Chief People Officer to help guide the Company’s strategic growth.

Anticipated Key Milestones:

  • Agazisiran (CFB) Phase 2 data:
    • IgAN - mid-2027 (9-month UPCR reduction data), 2H 2027 (1-year eGFR stabilization data)
    • C3G - 2H 2027
    • PNH - 2H 2027
  • Onvuzosiran (PKK): Phase 3 STOP-HAE topline data by year-end 2027
  • ADX-626 (FXI): Phase 2a/b initiation in SSP in 2027
  • ADX-077 (OBE1): Phase 1 initiation in obesity in 2027
  • ADX-199 (APP): Phase 1 initiation by year-end 2027 or early 2028

Third Quarter 2026 Financial Results

As of September 30, 2026, ADARx had cash, cash equivalents and short-term investments of $901.0 million. This amount excludes net proceeds of approximately $62.3 million received on October 1, 2026 from the issuance and sale of an additional 3,937,500 shares of common stock pursuant to the underwriters’ exercise in full of their option to purchase additional shares at the IPO price of $17.00 per share. The Company expects its existing cash, cash equivalents and short-term investments, together with those proceeds, to fund its projected operating expenses and capital expenditure requirements into 2030.

Collaboration revenue was $2.2 million for the quarter ended September 30, 2026, compared to $1.6 million for the same period in 2025. In each case, such revenue was recognized under the Collaboration and License Option Agreement with the Puerto Rico branch of AbbVie Biotechnology Ltd based on the Company’s performance of research and development services completed during the respective periods.

Research and development (R&D) expenses were $26.7 million for the quarter ended September 30, 2026, compared to $19.4 million for the same period in 2025. The increase was primarily due to increases in external R&D expenses attributable to therapeutic candidates, preclinical and other external R&D expenses, and personnel-related expenses, partially offset by a decrease in other internal R&D expenses.

General and administrative (G&A) expenses were $7.7 million for the quarter ended September 30, 2026, compared to $5.1 million for the same period in 2025. The increase was primarily due to an increase in personnel-related costs, professional fees and other expenses, other G&A related costs, and stock-based compensation expenses.

Net loss was $28.1 million for the quarter ended September 30, 2026, compared to a net loss of $17.9 million for the same period in 2025.

Upcoming Events

ADARx expects to participate in the following upcoming investor conference:

  • UBS Global Biopharma Conference - London, Monday, November 16, 2026 at 2:00 pm GMT

About ADARx Pharmaceuticals

ADARx Pharmaceuticals, Inc. is a late-clinical stage biotechnology company focused on developing next-generation RNA therapeutics designed to treat a broad spectrum of diseases. The Company is focused on advancing and expanding its pipeline of highly potent, selective and durable small interfering RNA (“siRNA”) therapeutic candidates, including three clinical-stage programs and two advanced preclinical programs. ADARx’s three hepatic-targeted programs are agazisiran, onvuzosiran and ADX-626, and its two extrahepatic-targeted programs are ADX-077 and ADX-199. Beyond its named programs, ADARx plans to continue to leverage its proprietary technologies to strategically expand its pipeline of next-generation siRNA therapeutics. ADARx’s goal is to control the expression of specific disease drivers with highly selective RNA targeted therapies, delivering life-changing treatments for patients with urgent unmet medical needs.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements regarding: ADARx’s cash runway; the anticipated timing of data from ADARx’s clinical trials; the anticipated initiation and timing of ADARx’s preclinical studies and clinical trials; the potential of agazisiran as a pipeline-in-a-product opportunity; the potential safety, efficacy, durability and other benefits of ADARx’s therapeutic candidates and technologies, including its extrahepatic delivery technology; ADARx's ability to advance its clinical programs in parallel, advance its preclinical candidates into clinical development and submit additional INDs; the anticipated use of the proceeds from the IPO and concurrent private placement; the potential of siRNA therapeutics to address a broader range of diseases; and ADARx’s strategy, plans and objectives. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “project,” “should,” “target,” “will,” “would” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are based on ADARx’s current expectations and assumptions and are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements, including risks related to the timing, progress and results of ADARx’s preclinical studies and clinical trials, ADARx’s ability to obtain regulatory clearances and approvals for its therapeutic candidates, ADARx’s reliance on third parties and ADARx’s capital needs. For a further description of these and other risks and uncertainties, see the section titled “Risk Factors” in ADARx’s final prospectus filed with the Securities and Exchange Commission (SEC) pursuant to Rule 424(b), ADARx’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 to be filed with the SEC and ADARx’s other filings with the SEC. Forward-looking statements speak only as of the date of this press release, and you should not place undue reliance on them. Except as required by applicable law, ADARx undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

 
ADARx PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEET
(IN THOUSANDS)
(UNAUDITED)
       
  September 30,  December 31, 
  2026  2025 
       
Assets      
Current assets:      
Cash and cash equivalents $570,610  $66,517 
Short-term investments  330,397   413,479 
Prepaid expenses and other current assets  17,507   13,379 
Total current assets  918,514   493,375 
Property and equipment, net  4,397   4,734 
Operating lease right-of-use assets  6,053   7,336 
Other non-current assets  100   2,210 
Total assets $929,064  $507,655 
Liabilities, convertible preferred stock, and stockholders’ equity (deficit)      
Current liabilities:      
Accounts payable $9,346  $5,844 
Accrued expenses and other current liabilities  11,594   6,371 
Deferred revenue, current portion  20,924   16,557 
Lease liabilities, current portion  1,710   1,713 
Total current liabilities  43,574   30,485 
Lease liabilities, less current portion  4,749   6,028 
Deferred revenue, less current portion  305,524   314,994 
Other long-term liabilities  815   781 
Total liabilities  354,662   352,288 
Commitments and contingencies      
Convertible preferred stock:      
Series A convertible preferred stock, $0.0001 par value; zero and 31,315,236 shares authorized as of September 30, 2026 and December 31, 2025; zero and 26,726,324 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively  —   37,553 
Series B convertible preferred stock, $0.0001 par value; zero and 14,653,302 shares authorized as of September 30, 2026 and December 31, 2025; zero and 12,506,015 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively  —   74,787 
Series B-1 convertible preferred stock, $0.0001 par value; zero and 6,913,353 shares authorized as of September 30, 2026 and December 31, 2025; zero and 5,900,272 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively  —   45,710 
Series C convertible preferred stock, $0.0001 par value; zero and 24,038,463 shares authorized as of September 30, 2026 and December 31, 2025; zero and 20,515,872 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively  —   199,572 
Stockholders’ equity (deficit):      
Preferred stock, $0.0001 par value; 10,000,000 and zero shares authorized, zero shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively  —   — 
Common stock, $0.0001 par value; 999,999,999 and 102,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 107,255,963 and 9,659,572 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively  11   — 
Additional paid-in capital  873,785   16,489 
Accumulated other comprehensive (loss) income  (2,152)  1,955 
Accumulated deficit  (297,242)  (220,699)
Total stockholders’ equity (deficit)  574,402   (202,255)
Total liabilities, convertible preferred stock, and stockholders’ equity (deficit) $929,064  $507,655 
         


 
ADARx PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS)
(UNAUDITED)
       
  Three Months Ended September 30,  Nine Months Ended September 30, 
  2026  2025  2026  2025 
Revenue:            
Collaboration revenue $2,217  $1,555  $5,103  $1,763 
Operating expenses:            
Research and development  26,713   19,416   75,032   49,381 
General and administrative  7,681   5,146   19,195   14,399 
Total operating expenses  34,394   24,562   94,227   63,780 
Loss from operations  (32,177)  (23,007)  (89,124)  (62,017)
Other income, net:            
Interest income  3,479   4,622   11,234   9,363 
Other income  581   502   1,347   1,127 
Total other income, net  4,060   5,124   12,581   10,490 
Net loss $(28,117) $(17,883) $(76,543) $(51,527)
Other comprehensive income (loss):            
Foreign currency translation adjustment  3   (6)  32   (28)
Unrealized (losses) gains on available-for-sale securities  (1,372)  435   (4,139)  1,236 
Total comprehensive loss $(29,486) $(17,454) $(80,650) $(50,319)
Net loss per share, basic and diluted $(1.74) $(1.85) $(6.46) $(5.35)
Weighted-average shares outstanding, basic and diluted  16,127,078   9,654,689   11,840,561   9,632,648 
                 




Contacts
Investors: ir@adarx.com
Media: teri@redhousecomms.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did ADARx raise in its IPO and concurrent private placement?

ADARx raised approximately $602.5 million in aggregate gross proceeds. The IPO generated $513.2 million before underwriting discounts, commissions and other offering expenses, while the concurrent private placement with AbbVie generated $89.3 million.

How long does ADARx expect its cash to fund operations?

ADARx expects its existing cash, cash equivalents and short-term investments, together with the October 1 option-exercise proceeds, to fund projected operating expenses and capital expenditure requirements into 2030. The September 30 balance was $901.0 million, excluding approximately $62.3 million in net proceeds received October 1.

What dosing changes is ADARx planning for agazisiran and ADX-626 trials?

ADARx intends to explore additional dosing regimens in the agazisiran Phase 2 IgAN and paroxysmal nocturnal hemoglobinuria trials and higher ADX-626 doses in its planned Phase 2 trial. Higher ADX-626 doses will not be evaluated after the third dose cohort, 400 mg, in the ongoing Phase 1 trial.

Keep reading